REGENCY
Roche’s Gazyva Shows Promising Results in Phase 3 Lupus Nephritis Trial, Paving Way for Expanded Use
Gazyva, lupus nephritis, Roche, phase 3 trial, REGENCY study, obinutuzumab, kidney disease, autoimmune disease, treatment options.
Actionable Insights Powered by AI
Gazyva, lupus nephritis, Roche, phase 3 trial, REGENCY study, obinutuzumab, kidney disease, autoimmune disease, treatment options.